The University of Southampton
University of Southampton Institutional Repository

Moving towards a Treatable Traits model of care for the management of obstructive airways diseases

Moving towards a Treatable Traits model of care for the management of obstructive airways diseases
Moving towards a Treatable Traits model of care for the management of obstructive airways diseases

Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airways diseases. Both are complex and heterogeneous. Traditionally, clinical guidelines have advocated a stepwise approach to pharmacotherapy of asthma and COPD, but there is increasing realization that both require a more personalized and precise management approach. To this end, a management strategy based on the so-called Treatable Traits has been proposed. Emerging evidence suggests that this model improves relevant outcomes in patients with chronic airway diseases but further research is needed to guide implementation. This review discusses the challenges, opportunities, and hurdles that its implementation will have to face.

Asthma, Biomarkers, COPD, Targeted therapy
0954-6111
Agusti, Alvar
e916da0b-126c-45bf-8ebe-af737fd32344
Barnes, Neil
bab83bf7-6c59-4cba-878e-9dc95e154fa8
Cruz, Alvaro A.
35c073a4-664c-42b0-9705-f3416d5f8ade
Gibson, Peter G.
b97e6518-ae09-4080-b76a-e6025647a79f
Heaney, Liam G.
80e8956f-63cb-4637-b916-9b13f3420761
Inoue, Hiromasa
8fc1db89-1f5f-4fe9-833c-8b38d62eca16
Leather, David
ac7e6999-7d5e-41b8-bd08-63a83d784600
Martinez, Fernando J.
035c439e-6219-442e-a408-aa64f6369256
McDonald, Vanessa M.
43deacee-d810-4436-9d4f-f76daaa96f17
Oppenheimer, John
dc3b5d31-c8cb-43ba-9885-234cfdf8c6e5
Papi, Alberto
8447eef8-34fd-482e-8e91-f8231acd05f7
Pavord, Ian D.
9718f25b-b28d-47d2-b19d-6c5ead4f1717
Thomas, Mike
997c78e0-3849-4ce8-b1bc-86ebbdee3953
Walker, Samantha
363eae9c-eb25-4e6c-adb0-ae7d78e205e8
Yates, Louisa
4115a95d-1fad-4878-815d-a178f6ad7690
Agusti, Alvar
e916da0b-126c-45bf-8ebe-af737fd32344
Barnes, Neil
bab83bf7-6c59-4cba-878e-9dc95e154fa8
Cruz, Alvaro A.
35c073a4-664c-42b0-9705-f3416d5f8ade
Gibson, Peter G.
b97e6518-ae09-4080-b76a-e6025647a79f
Heaney, Liam G.
80e8956f-63cb-4637-b916-9b13f3420761
Inoue, Hiromasa
8fc1db89-1f5f-4fe9-833c-8b38d62eca16
Leather, David
ac7e6999-7d5e-41b8-bd08-63a83d784600
Martinez, Fernando J.
035c439e-6219-442e-a408-aa64f6369256
McDonald, Vanessa M.
43deacee-d810-4436-9d4f-f76daaa96f17
Oppenheimer, John
dc3b5d31-c8cb-43ba-9885-234cfdf8c6e5
Papi, Alberto
8447eef8-34fd-482e-8e91-f8231acd05f7
Pavord, Ian D.
9718f25b-b28d-47d2-b19d-6c5ead4f1717
Thomas, Mike
997c78e0-3849-4ce8-b1bc-86ebbdee3953
Walker, Samantha
363eae9c-eb25-4e6c-adb0-ae7d78e205e8
Yates, Louisa
4115a95d-1fad-4878-815d-a178f6ad7690

Agusti, Alvar, Barnes, Neil, Cruz, Alvaro A., Gibson, Peter G., Heaney, Liam G., Inoue, Hiromasa, Leather, David, Martinez, Fernando J., McDonald, Vanessa M., Oppenheimer, John, Papi, Alberto, Pavord, Ian D., Thomas, Mike, Walker, Samantha and Yates, Louisa (2021) Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory Medicine, 187, [106572]. (doi:10.1016/j.rmed.2021.106572).

Record type: Review

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airways diseases. Both are complex and heterogeneous. Traditionally, clinical guidelines have advocated a stepwise approach to pharmacotherapy of asthma and COPD, but there is increasing realization that both require a more personalized and precise management approach. To this end, a management strategy based on the so-called Treatable Traits has been proposed. Emerging evidence suggests that this model improves relevant outcomes in patients with chronic airway diseases but further research is needed to guide implementation. This review discusses the challenges, opportunities, and hurdles that its implementation will have to face.

Text
Full text Agusti et al 2021 - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)

More information

Accepted/In Press date: 6 August 2021
Published date: 13 August 2021
Additional Information: Funding Information: AP reports grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Edmondpharma, Fondazione Maugeri, GlaxoSmithKline, Menarini, Mundipharma, Novartis, Roche, Sanofi/Regeneron, TEVA, and Zambon. Funding Information: LGH has received institutional grant support from Aerocrine, Amgen, AstraZeneca, Genentech/Hoffman-La Roche, GlaxoSmithKline, Medimmune, Novartis UK, and Vitalograph. He has also received speaker's honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Napp Pharmaceuticals, and personal fees from AstraZeneca, Circassia, Evelo Biosciences, GlaxoSmithKline, Hoffman-la-Roche/Genentech Inc, Novartis, Sanofi, Teva, and Theravance; all outside of the published work. Funding Information: PGG has received speaker's honoraria from AstraZeneca, GlaxoSmithKline and Novartis and grant support from AstraZeneca and GlaxoSmithKline. Funding Information: HI has participated in Advisory boards and has received speaker's honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Chugai, GlaxoSmithKline, Kyorin, Merck Sharp & Dohme, Novartis, and Sanofi. He has also received research/educational grant support from Boehringer Ingelheim, Chugai, GlaxoSmithKline, Kyorin, Merck Sharp & Dohme, Novartis, Ono, Pfizer, Sanofi, Shionogi, Taiho, and Teijin-Pharma. Funding Information: VMMcD has received grant support from AstraZeneca and GlaxoSmithKline, and personal fees from AstraZeneca, GlaxoSmithKline, and Novartis; outside of the published work. Funding Information: IDP has received grant support from Chiesi, support from Regeneron and Sanofi, and non-financial support from Excerpta Medica, during the conduct of the study. He has also received grant support from Chiesi and support outside of the published work from Aerocrine AB, Almirall, AstraZeneca, Boehringer Ingelheim, Circassia, Dey Pharma, Genentech, GlaxoSmithKline, Knopp Biosciences, Merck, Merck Sharp & Dohme, Napp Pharmaceuticals, Novartis, Regeneron, RespiVert, Sanofi, Schering-Plough, and Teva. Funding Information: FJM reports support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Raziel Therapeutics during the conduct of the study. Outside of the published work, FJM reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Patara Pharma, ProterrixBio, Sanofi/Regeneron and Teva, and other/non-financial support from AbbVie, Afferent/Merck, Biogen, Bridge Biotherapeutics, and Gilead. He also reports grants from NIH, Canadian Respiratory Network, and ProMedior/Roche. Publisher Copyright: © 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
Keywords: Asthma, Biomarkers, COPD, Targeted therapy

Identifiers

Local EPrints ID: 452967
URI: http://eprints.soton.ac.uk/id/eprint/452967
ISSN: 0954-6111
PURE UUID: 74eca6eb-4d0b-4116-b973-8a5721132b52

Catalogue record

Date deposited: 07 Jan 2022 11:59
Last modified: 17 Mar 2024 12:50

Export record

Altmetrics

Contributors

Author: Alvar Agusti
Author: Neil Barnes
Author: Alvaro A. Cruz
Author: Peter G. Gibson
Author: Liam G. Heaney
Author: Hiromasa Inoue
Author: David Leather
Author: Fernando J. Martinez
Author: Vanessa M. McDonald
Author: John Oppenheimer
Author: Alberto Papi
Author: Ian D. Pavord
Author: Mike Thomas
Author: Samantha Walker
Author: Louisa Yates

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×